
Reproduced By Oxyfiles.org
OxyFile #262
S 578 IS
105th CONGRESS
1st Session
S. 578
To permit an individual to be treated by a health care practitioner with any
method of medical treatment such individual requests, and for other
purposes.
IN THE SENATE OF THE UNITED STATES
April 15, 1997
Mr. DASCHLE (for himself, Mr. HARKIN, Mr. HATCH, Mr. GRASSLEY, Mr. ABRAHAM,
Mr. REID, Mr. INOUYE, Mr. BAUCUS, Mr. CRAIG, Mr. KEMPTHORNE, and Mr. THOMAS)
introduced the following bill; which was read twice and referred to the
Committee on Labor and Human Resources
A BILL
To permit an individual to be treated by a health care practitioner with any
method of medical treatment such individual requests, and for other
purposes.
Be it enacted by the Senate and House of Representatives of the United
States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the `Access to Medical Treatment Act'.
SEC. 2. DEFINITIONS.
In this Act: (1) ADVERTISING CLAIMS- The term `advertising claims' means any
representations made or suggested by statement, word, design, device, sound,
or any combination thereof with respect to a medical treatment.
(2) DANGER- The term `danger' means any negative reaction that-- (B) occurred as a result of a method of medical treatment;
(C) would not otherwise have occurred; and
(D) is more serious than reactions experienced with routinely used
medical treatments for the same medical condition or conditions.
(3) DEVICE- The term `device' has the same meaning given such term in
section 201(h) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
321(h)).
(4) DRUG- The term `drug' has the same meaning given such term in
section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
321(g)(1)).
(5) FOOD- The term `food'-- (A) has the same meaning given such term in section 201(f) of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321(f)); and
(B) includes a dietary supplement as defined in section 201(ff) of
such Act.
(6) HEALTH CARE PRACTITIONER- The term `health care practitioner' means
a physician or another person who is legally authorized to provide health
professional services in the State in which the services are provided.
(7) LABEL- The term `label' has the same meaning given such term in
section 201(k) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
321(k)).
(8) LABELING- The term `labeling' has the same meaning given such term
in section 201(m) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
321(m)).
(9) LEGAL REPRESENTATIVE- The term `legal representative' means a parent
or an individual who qualifies as a legal guardian under State law.
(10) MEDICAL TREATMENT- The term `medical treatment' means any food,
drug, device, or procedure that is used and intended as a cure, mitigation,
treatment, or prevention of disease.
(11) SELLER- The term `seller' means a person, company, or organization
that receives payment related to a medical treatment of a patient of a
health practitioner, except that this term does not apply to a health care
practitioner who receives payment from an individual or representative of such
individual for the administration of a medical treatment to such individual.
SEC. 3. ACCESS TO MEDICAL TREATMENT.
(a) IN GENERAL- Notwithstanding any other provision of law, and except as
provided in subsection (b), an individual shall have the right to be treated
by a health care practitioner with any medical treatment (including a medical
treatment that is not approved, certified, or licensed by the Secretary of
Health and Human Services) that such individual desires or the legal
representative of such individual authorizes if-- (1) such practitioner has personally examined such individual and agrees
to treat such individual; and
(2) the administration of such treatment does not violate licensing
laws.
(b) MEDICAL TREATMENT REQUIREMENTS- A health care practitioner may provide
any medical treatment to an individual described in subsection (a) if-- (1) there is no reasonable basis to conclude that the medical treatment
itself, when used as directed, poses an unreasonable and significant risk of
danger to such individual;
(2) in the case of an individual whose treatment is the administration
of a food, drug, or device that has to be approved, certified, or licensed
by the Secretary of Health and Human Services, but has not been approved,
certified, or licensed by the Secretary of Health and Human Services--
(A) such individual has been informed in writing that such food, drug,
or device has not yet been approved, certified, or licensed by the
Secretary of Health and Human Services for use as a medical treatment of
the medical condition of such individual; and
(B) prior to the administration of such treatment, the practitioner
has provided the patient a written statement that states the following:
`WARNING: This food, drug, or device has not been declared to be
safe and effective by the Federal Government and any individual who uses
such food, drug, or device, does so at his or her own risk.';
(3) such individual has been informed in writing of the nature of the
medical treatment, including-- (A) the contents and methods of such treatment;
(B) the anticipated benefits of such treatment;
(C) any reasonably foreseeable side effects that may result from such
treatment;
(D) the results of past applications of such treatment by the health
care practitioner and others; and
(E) any other information necessary to fully meet the requirements for
informed consent of human subjects prescribed by regulations issued by the
Food and Drug Administration;
(4) except as provided in subsection (c), there have been no advertising
claims made with respect to the efficacy of the medical treatment by the
practitioner;
(5) the label or labeling of a food, drug, or device that is a medical
treatment is not false or misleading; and
(6) such individual-- (A) has been provided a written statement that such individual has
been fully informed with respect to the information described in
paragraphs (1) through (4);
(B) desires such treatment; and
(C) signs such statement.
(c) CLAIM EXCEPTIONS- (1) REPORTING BY A PRACTITIONER- Subsection (b)(4) shall not apply to an
accurate and truthful reporting by a health care practitioner of the results
of the practitioner's administration of a medical treatment in recognized
journals, at seminars, conventions, or similar meetings, or to others, so
long as the reporting practitioner has no direct or indirect financial
interest in the reporting of the material and has received no financial
benefits of any kind from the manufacturer, distributor, or other seller for
such reporting. Such reporting may not be used by a manufacturer,
distributor, or other seller to advance the sale of such treatment.
(2) STATEMENTS BY A PRACTITIONER TO A PATIENT- Subsection (b)(4) shall
not apply to any statement made in person by a health care practitioner to
an individual patient or an individual prospective patient.
(3) DIETARY SUPPLEMENTS STATEMENTS- Subsection (b)(4) shall not apply to
statements or claims permitted under sections 403B and 403(r)(6) of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 343-2 and 343(r)(6)).
SEC. 4. REPORTING OF A DANGEROUS MEDICAL TREATMENT.
(a) HEALTH CARE PRACTITIONER- If a health care practitioner, after
administering a medical treatment, discovers that the treatment itself was a
danger to the individual receiving such treatment, the practitioner shall
immediately report to the Secretary of Health and Human Services the nature of
such treatment, the results of such treatment, the complete protocol of such
treatment, and the source from which such treatment or any part thereof was
obtained.
(b) SECRETARY- Upon confirmation that a medical treatment has proven
dangerous to an individual, the Secretary of Health and Human Services shall
properly disseminate information with respect to the danger of the medical
treatment.
SEC. 5. REPORTING OF A BENEFICIAL MEDICAL TREATMENT.
If a health care practitioner, after administering a medical treatment
that is not a conventional medical treatment for a life-threatening medical
condition or conditions, discovers that such medical treatment has positive
effects on such condition or conditions that are significantly greater than
the positive effects that are expected from a conventional medical treatment
for the same condition or conditions, the practitioner shall immediately make
a reporting, which is accurate and truthful, to the Office of Alternative
Medicine of-- (1) the nature of such medical treatment (which is not a conventional
medical treatment);
(2) the results of such treatment; and
(3) the protocol of such treatment.
SEC. 6. TRANSPORTATION AND PRODUCTION OF FOOD, DRUGS, DEVICES, AND OTHER
EQUIPMENT.
Notwithstanding any other provision of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 201 et seq.), a person may-- (1) introduce or deliver into interstate commerce a food, drug, device,
or any other equipment; and
(2) produce a food, drug, device, or any other equipment,
solely for use in accordance with this Act if there have been no
advertising claims by the manufacturer, distributor, or seller.
SEC. 7. VIOLATION OF THE CONTROLLED SUBSTANCES ACT.
A health care practitioner, manufacturer, distributor, or other seller may
not violate any provision of the Controlled Substances Act (21 U.S.C. 801 et
seq.) in the provision of medical treatment in accordance with this Act.
SEC. 8. PENALTY.
A health care practitioner who knowingly violates any provisions under
this Act shall not be covered by the protections under this Act and shall be
subject to all other applicable laws and regulations.
END